Black Barley Study - Barley to Support Food and Drink Innovation (RI-B7-3)
BB
Barley to Support Food and Drink Innovation (RI-B7-3)
1 other identifier
interventional
11
1 country
1
Brief Summary
Sustained postprandial hyperglycaemia is an independent risk factor for cardiovascular complications and death. Intensive glucose control is the predominant factor to prevent the development of chronic complications in Type 2 Diabetes Mellitus (T2DM). The investigators have shown that phytochemical-rich extracts (in this case anthocyanins and their derivatives) can attenuate glucose response and there is also strong evidence for the role of fibre. Here a selected barley line (rich in anthocyanins and (1,3;1,4)-β-glucan) will be compared to a control barley and control wheat in an acute human dietary intervention (with n=15 healthy volunteers) to explore the potential to modulate postprandial glycaemia and insulinaenemia. An additional secondary outcome will include metabolomics analysis of the blood plasma and urine to detect differences in bioactive compounds including phytochemical metabolites. This will help ensure that barley lines being bred for human food can also deliver benefits for health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable type-2-diabetes
Started Jul 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 27, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 28, 2024
CompletedFirst Submitted
Initial submission to the registry
October 31, 2024
CompletedFirst Posted
Study publicly available on registry
November 4, 2024
CompletedNovember 12, 2024
November 1, 2024
10 months
October 31, 2024
November 7, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Postprandial blood glucose levels
Modulation of postprandial blood glucose levels after acute consumption of the Black barley, Bere barley and the Wheat breads.
5 hours
Postprandial insulin levels
Modulation of postprandial insulin levels after acute consumption of the Black barley, Bere barley and the Wheat breads.
5 hours
Secondary Outcomes (1)
Concentration of phytochemical metabolites in the systemic circulation
5 hours
Study Arms (3)
Control Wheat Bread
ACTIVE COMPARATORControl Wheat Bread will be prepared to the same formulation as white wheat bread.
Berneray Bere barley bread
EXPERIMENTALBerneray Bere barley bread will be prepared to a formulation as for the white wheat bread, but the wheat flour will be replaced with Berneray Bere barley flour.
Black Barley bread
EXPERIMENTALBlack Barley bread will be prepared to a formulation as for the white wheat bread, but the wheat flour will be replaced with Black Barley flour.
Interventions
Ingredients: Wheat Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
Ingredients: Berneray Bere Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
Ingredients: Black Barley Flour, Salt, Water, Allinson's Dried Active Yeast, Sugar
Eligibility Criteria
You may qualify if:
- Apparently healthy male and female subjects with Diabetes Risk Score ≥ 7 points
You may not qualify if:
- Type 1 diabetes
- Type 2 diabetes controlled with medication
- Coeliac Disease
- Eating disorders (anorexia, bulimia, binge eating or night eating syndrome)
- Food allergies/intolerances
- Any significant health issues
- Breastfeeding/ Pregnancy
- Addiction to any substances
- Are unable to give written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Aberdeen, The Rowett Institute
Aberdeen, AB25 2ZD, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wendy Russell
University of Aberdeen
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 31, 2024
First Posted
November 4, 2024
Study Start
July 27, 2022
Primary Completion
May 15, 2023
Study Completion
June 28, 2024
Last Updated
November 12, 2024
Record last verified: 2024-11
Data Sharing
- IPD Sharing
- Will not share